

## CONTINUOUS MANUFACTURING FOR BIOLOGICS & VACCINES

Sue Behrens ISPE Product Show Track 2, Session 3 September 26, 2018







## Why? Advantages Quality Medi Formulation Buffer (excipients) > Steady State Operation **Generic Continuous Process** > Improved Stability > Closed Processing > PAT/Inline Process Control Primary Polishing larificatio ormulatio Capture > Continuous Data Acquisition Cost Host Cell Prote (Water) Impurities (e.g., DNA) > Reduced scale (capital, footprint) Perfusior Bioreacto > Minimize impact of changeovers A. Zydney, Current Opinion in Chem Eng, Nov 2015, 10(8-13) > Lower labor utilization **Fully Continuous Process:** > Minimum inventory Perfusion Flexibility > Steady supply from ongoing production > Variable scale production ISPE. Connecting Pharmaceutical Knowledge ispe.org 5















Perfusion				
> Centrifugation				
> Microcarriers				
> Rocker Bioreac	tors w/ Perfusion mem	ıbrane		







## <section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header>













## Challenges for implementation What's next?

- > Process Knowledge
  - Need detailed understanding of diverse conditions
  - Understanding impact of deviation
  - Response to Process perturbations
- > Operational
  - Broader training for technicians
  - Supply chain management
  - Harmonization of equipment
- > Regulatory
  - Complexity of "batch" definition and release strategy
  - Implement for new products with QbD data
  - Transition from legacy manufacturing process

This Photo by Unknown Author is licensed under CC BY-ND

V ISPE.

Connecting Pharmaceutical Knowledge

ispe.org | 24



